Pharmaceuticals
Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy
- Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
2023-10-27 21:07
3194
Henlius Announces NMPA Approvals of Two ADC Candidates for IND
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the investigational new drug (IND) applications of HLX42 for Injection, a novel EGFR-targeting antibody-drug conjugate (ADC) as well as HLX43, a novel PD-L1-targeting ADC, have been approved by the Na...
2023-10-27 20:16
3289
Peijia Medical Presents Early Clinical Findings of GeminiOne® TEER Device at TCT 2023
SUZHOU, China, Oct. 27, 2023 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at ...
2023-10-27 20:00
1719
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerc...
2023-10-27 19:47
2530
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India
* The footprint of serplulimab now includes the United States, Europe, Southeast Asia, MENA, and India * Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalties and up to €143 million in regulatory and commerci...
2023-10-27 19:13
6036
NX Ireland Acquires GDP Certification for Company-owned Warehouse
TOKYO, Oct. 27, 2023 /PRNewswire/ -- Nippon Express (Ireland) Ltd. (hereafter "NX Ireland"), a group company of NIPPON EXPRESS HOLDINGS, INC., has received Good Distribution Practice (GDP) certification from the Irish Exporters Association (IEA), effectiveSeptember 21, for the temporary storage a...
2023-10-27 14:00
2117
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Pharmaceutical Administration Bureau of...
2023-10-27 13:45
2176
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
SHANGHAI, Oct. 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will make a late-breaking poster present...
2023-10-27 08:22
2249
Noted National TCM Master Inaugurates New Infinitus Research and Technology Laboratory
GUANGZHOU, China, Oct. 27, 2023 /PRNewswire/ – The unveiling ceremony for the joint laboratory, a collaboration between Infinitus and theShandong University of Traditional Chinese Medicine dedicated toXuezhuo-turbid blood research, took place at Infinitus Plaza. The event drew attention from over...
2023-10-27 08:00
1962
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
* Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services forHope Medicine's first-in-class monoclonal antibody drug, HMI-115. * The first-in-class mAb will benefit endometriosis and androgenetic alopecia patients. SHANGHAI, Oct. 26, 20...
2023-10-26 22:49
1540
Clarity and PSI kick off SAR-bisPSMA Phase III
SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...
2023-10-26 21:00
1458
YS Biopharma Announces Receipt of Nasdaq Notice
GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-26 20:30
3456
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...
2023-10-26 19:00
1701
Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China
LAUSANNE, Switzerland, Oct. 26, 2023 /PRNewswire/ -- Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker fo...
2023-10-26 18:33
2379
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the tre...
2023-10-26 18:18
2616
World Psoriasis Day 2023: Access for All
STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- Every year on World Psoriasis Day, October 29th, the international psoriatic disease community unites to raise awareness and fight for progress. The theme of 2023, "Access for All," underscores the vital need for Universal Health Coverage (UHC) to ensure t...
2023-10-26 16:00
2020
Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer
CHENGDU, China, Oct. 26, 2023 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) convened its annual meeting inMadrid, Spain, from October 20th to 24th, 2023. As the preeminent academic gathering in the field ofoncology, it brought together global experts in oncology to share the la...
2023-10-26 12:58
2088
The International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair Held
PHUKET, Thailand, Oct. 26, 2023 /PRNewswire/ -- During the period from October 25 to 27, 2023, the International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair is held in Thailand. Over 200 experts and scholars from more than 20 countries ...
2023-10-26 10:29
1805
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with theinvestigational product * No safety concerns were raised based on the evaluation of the data presented ...
2023-10-26 07:00
1643
Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US
GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country. With clinics now operating in Georgia, Texas, Illinois, Tenness...
2023-10-25 23:23
1371
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 293 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 290 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9284
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7761
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
6412
